Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (October 5th Preview)
-
Pneumococcal vaccine Phase 3 win for Vaxcyte
Vaxcyte said its next-generation pneumococcal vaccine, VAX-31, met key endpoints in a Phase 3 trial in adults age 50 and older, setting up a direct push into the crowded market dominated by Pfizer and Merck. The trial randomized just over 3,500 participants across VAX-31, Prevnar, and Capvaxive arms and evaluated antibody responses across targeted serotypes.
-
Regulatory expansion for Jaypirca in CLL
Lilly’s Jaypirca received a label expansion for use as a first-line therapy in chronic lymphocytic leukemia, marking another step for the BTK/CDK pathway strategy in earlier lines of treatment. The update tightens the competitive landscape as oncologists shift toward targeted regimens earlier in disease course.
-
Rare disease dealmaking: Shionogi acquires IntraBio for $2B
Shionogi agreed to acquire IntraBio, a Texas-based rare-disease company, for $2 billion upfront, adding a marketed treatment covering two inherited conditions to its expanding rare disease portfolio. The move also extends Shionogi’s emphasis on oral small molecules and real-world commercial assets as it builds out its downstream pipeline.
-
Neuroscience collaboration: Roche pays $100M upfront to Alector
Roche is paying Alector $100 million upfront in a new partnership focused on neuroscience and Parkinson’s disease efforts. The deal arrives amid shifting collaboration dynamics at large biopharma as companies recalibrate prior licensing arrangements and seek new internal/external bets in neurodegeneration.
-
Rare kidney and liver rare disease co-development: CSL and Alentis
CSL struck a collaboration with Alentis to co-develop lixudebart, an anti-fibrosis candidate for life-threatening rare kidney and liver diseases, with $355 million paid upfront plus potential milestone payments reaching $1.2 billion. The structure reinforces CSL’s push into specialty rare disease biology and adds another fibrosis asset aimed at progressing beyond preclinical validation into development with a major pharma partner.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.